P11.23.B Neurological symptoms independently associate with overall survival in patients with melanoma brain metastases

Abstract Background Based on the rising detection of asymptomatic brain metastases (BM) and remarkable intracranial responses targeted- immunotherapy in specific subgroups BM patients, we aimed to evaluate clinical characteristics prognostic value neurological symptoms from melanoma. Material Methods 670 patients with newly diagnosed melanoma were identified Vienna Brain Metastasis Registry. We performed retrospective chart review statistical outcome analyses. Results 370/670 (55.2%) presented including deficits (316/370; 85.4%), signs increased pressure (126/370; 34.1%) epileptic seizures (53/370; 14.3%). 57.6% (80/139) BRAF mutated at diagnosis. Absence diagnosis was associated a longer median overall survival after time (7 vs. 5 months; p< 0.001; log-rank test). In multivariate analysis diagnosis-specific graded assessment (DS-GPA: HR:1.4; 95% CI, 1.25-1.48; p<0.001) for using molecular markers (Melanoma-molGPA: HR:0.8; 0.66 -0.92; p<0.001), presence (HR 0.8; 0.69 -0.96; p=0.003/ HR:0.6; 0.59-0.72; found be independently prognosis respectively. Conclusion: Neurological are an independent strong factor patients. Our results argue integration into